Evaro is a UK-based healthcare technology company (dba Total Access Health Ltd.) that builds an AI-powered digital health platform enabling instant medical access, AI-driven asynchronous consultations, diagnoses, and next-day prescriptions for non-urgent conditions, covering up to 40-80% of typical GP-handled issues like menopause, erectile dysfunction, acne, eczema, and psoriasis.[1][2][3][4] It serves individual patients directly via its D2C brand and partners with brands (e.g., Lovehoney, Patches, Clue) that integrate Evaro's services into their websites with a single line of code, solving overburdened healthcare access by bypassing GP appointments, pharmacy visits, and NHS restrictions through self-serve, convenient treatment.[1][2][5] From bootstrapped origins, Evaro has grown to support 600,000 patients, a 12,000 sq. ft. pharmacy, 400 medications for 80 conditions, a recent 10M-patient contract, and post-seed profitability, emphasizing regulatory compliance, 24-hour discreet delivery, and aftercare.[2][4][5]
Founded in 2017 in Norwich, UK, Evaro was co-founded by Dr. Thuria Wenbar, a frontline doctor with software development expertise, who identified frustrations in the UK's overburdened healthcare system—long waits, appointments, and prescription hurdles for minor issues.[1][3] Motivated by her dual medical and tech background, Wenbar built Evaro to empower self-serve health management via AI-driven consultations and private prescriptions, partnering with brands for specialized treatments.[1] Early traction came from bootstrapping, expanding from a flagship D2C service to a scalable platform; key pivots included raising $1.5M in seed funding, adopting custom agile processes (ripping apart traditional Scrum, using Gather Town for remote collaboration, and cheaper Google AI like Dialogue Flow), and growing to 13.5M patient records for ML training.[1][2][4]
Evaro rides the AI-healthcare democratization wave, addressing NHS bottlenecks amid rising demand for non-urgent care, where traditional systems fail on convenience for issues like sexual health or dermatology.[1][2] Timing aligns with post-pandemic telehealth acceleration, wearable data proliferation, and brand wellness integrations, fueled by market forces like aging populations, privacy-focused async consults, and cheaper AI alternatives to big models.[1][2][5] It influences the ecosystem by enabling non-health brands (e.g., sex toys, cosmetics) to offer prescription arms compliantly, expanding access while prioritizing safety—potentially reshaping D2C health from episodic to lifelong platforms.[2][5]
Evaro's trajectory points to a personalized holistic care pivot, leveraging patient/wearable data for proactive services beyond one-off prescriptions, scaling via partnerships and that 10M-patient contract.[2] Trends like multimodal AI, regulatory easing for digital health, and embedded wellness in e-commerce will propel growth, evolving Evaro from access innovator to relationship-builder in a fragmented market. As it humanizes overburdened care—echoing Wenbar's frontline vision—expect deeper ecosystem influence through compliant, instant health tech.
Evaro has raised $2.0M in total across 1 funding round.
Evaro's investors include Ada Ventures, CapitalT, Cornerstone VC.
Evaro has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $2.0M Seed | Ada Ventures, CapitalT, Cornerstone VC |
